- Investigator
- James Wymer
- Status
- Accepting Candidates
Research at a glance
Top areas of exploration
- Cell Line, Transformed , 1 publications
- Calcitonin Gene-Related Peptide , 1 publications
- Autocrine Communication , 1 publications
- Pseudobulbar Palsy , 1 publications
Research activity
Active clinical trials
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy type 3
- Investigator
- James Wymer
- Status
- Accepting Candidates
- Ages
- 18 Years - 60 Years
- Sexes
- All
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
- Investigator
- James Wymer
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
My publications
Filter publications
47 publications
2023
Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosis.
Annals of clinical and translational neurology
PubMed • Publisher's site2023
Functional Lingual Pressure Thresholds for Swallowing Safety and Efficiency Impairments in Amyotrophic Lateral Sclerosis.
Dysphagia
PubMed • Publisher's site2023
Maximum lingual pressure impacts both swallowing safety and efficiency in individuals with amyotrophic lateral sclerosis
Neurogastroenterology & Motility
PubMed • Publisher's site2023
Maximum Phonation Time as a Surrogate Marker for Airway Clearance Physiologic Capacity and Pulmonary Function in Individuals With Amyotrophic Lateral Sclerosis.
Journal of speech, language, and hearing research : JSLHR
PubMed • Publisher's site2023
Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis.
Expert review of neurotherapeutics
PubMed • Publisher's site